To view this email as a web page, click here

Subscribe

Advertise

 

 

 

 

 

 

February 01, 2019

Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications.

Featured Story

Roche halts phase 3 anti-Abeta Alzheimer’s test as AD flops rack up

Roche has stopped a pair of phase 3 Alzheimer’s disease trials after an interim analysis found they were unlikely to hit their primary endpoint. The setback wipes out near-term hopes of getting the AC Immune-partnered anti-Abeta antibody crenezumab to market.

Top Stories Of The Week

Humira biosimilars catch fire in Europe and could take half the market in a year: report

The mass exodus from AbbVie's Humira to biosimilars confirms what AbbVie’s executives have already admitted, which is that their initial estimate of a 20% revenue loss in Europe by 2020 was way too optimistic.

Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada

Celgene has signed on to a deal worth about $1 billion for a Canadian preclinical asset: a first-in-class small molecule that targets protein-protein interactions and epigenetic regulation in leukemia and lymphoma.

CVS puts Amgen's Aimovig in back seat behind Teva, Lilly migraine drugs

Amgen may have the first-mover advantage in the new class of CGRP migraine prevention drugs, but the company didn't get top billing with one major pharmacy benefits manager. CVS gave that to Teva and Eli Lilly instead.

Takeda’s dengue shot, rival to Sanofi's Dengvaxia, hits the mark in massive phase 3 study

It’s no secret Sanofi has had trouble with its world-first dengue vaccine, Dengvaxia, but that hasn't dissuaded Takeda. Its own dengue shot met its goal in a pivotal phase 3 study that covered eight countries and more than 20,000 participants.

Medtronic to buy EPIX and its RF-based cardiac ablation platform

Medtronic has moved to acquire EPIX Therapeutics and its catheter-based cardiac ablation system with plans to offer it alongside its own products and build out what the company describes as a “comprehensive suite of tools” for treating heart arrhythmias, including atrial fibrillation.

Preventing flu with an antibody-plus-Tamiflu universal vaccine

The flu virus' ability to rapidly mutate into vaccine-resistant strains has made the search for a universal vaccine all the more challenging. Researchers from the National Institutes of Health have found a new clue to providing broad-based protection against the flu—and it rests partly on Roche’s FDA-approved remedy Tamiflu.

Getting Real: Allergan taps Real Housewife to helm new CoolSculpting effort

Allergan’s crowd of fat-freezing celebrities just gained a Real Housewife. Sonja Morgan, one of the cast members of the Bravo series in New York City, is the face of the company's new “Let’s Get Real About Self-Care” promo for fat-freezing treatment CoolSculpting.

FDA finds more issues at Lupin plant it spanked in warning letter

The FDA in 2017 ripped Indian drugmaker Lupin in a warning letter for not learning from past mistakes. In a new visit to one of the two plants cited in that letter, the FDA has again found issues.

Abcam ups rabbit mAb presence with acquisition of Calico Biolabs

U.K. life sciences company Abcam has expanded its presence in rabbit monoclonal antibodies with the acquisition of California’s Calico Biolabs for an undisclosed price.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Whitepaper] RTSM/IRT: A Roadmap For Developing Systems That Address Current Frustrations

92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper.

[Whitepaper] Six API Challenges That could be Slowing your Development

Download this whitepaper to learn more.

[Whitepaper] Host Cell Protein Analysis in Biologic Drug Development

This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis.

[Whitepaper] Engaging Organized Customers in the Era of the Quadruple Aim

Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim

[Whitepaper] Integrating clinical research at the Point of Care—A New Operating Model

Clinical trials take too long and cost too much—here's what needs to change.

[Whitepaper] Better Market Intelligence With Smart Search

It’s never been more challenging to stay on top of competitive factors impacting your industry. Discover how AI can help competitive teams achieve more proactive market intelligence.

[POCKET GUIDE] 3 Steps To Supercharge Your Literature Search

Go from Search to Full-Text Scientific Papers in a Single Click!

[Whitepaper] Achieving launch excellence in the challenging healthcare markets of today

This white paper consists of original data and expert interviews. Download it today for exclusive tools, tips and analysis on achieving launch excellence in challenging pharma markets.

[Whitepaper] Liquid Biopsy Investor Toolkit

With the liquid biopsy market maturing and >80 companies still competing with liquid biopsy offerings, it is crucial for investors to be able to cut through the noise and identify the winners.

[Whitepaper] The 3DP Revolution: Planning Effective Brand Extension for In-Market Drugs

Get ahead of looming challenges in the market that include both generic products and new branded drugs.

[Infographic] Clinical Development Trends And The Impact On Clinical Trial Technology

New infographic shows trends in clinical development and the impact on randomization and trial supply management technology (RTSM).

[Webinar] Building the Business Case for Transformational RIM

Reduce the effort to create submissions and track registrations with a move to unified RIM. Watch the on-demand webinar.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.